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Expression of Twist increases the risk for recurrence and for poor
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Twist is a transcription factor that regulates the expression of tumour suppressors such as E-cadherin. We examined the distribution
and expression of Twist in human epithelial ovarian carcinoma (EOC) to examine its clinical significance. Paraffin sections from EOC
tissues (n¼82) were immunostained with Twist antibody, and the staining intensity was evaluated. The clinicopathological factors
examined were age, International Federation of Gynecology and Obstetrics staging, histological type, tumour grade, preoperative
value of CA125, peritoneal cytology, volume of ascites and residual tumour after cytoreductive surgery. Overall survival (OS) and
progression-free survival (PFS) were evaluated using the Kaplan–Meier method, and multivariate analysis was performed using the
Cox proportional hazard analysis. Of the 82 carcinomas, 49 (59.8%) cases were negative for Twist immunoexpression, and 33
(40.2%) were positive immunoexpression. When categorized into negative vs positive expression, Twist was not associated with any
of the clinicopathological parameters examined. However, positive Twist expression significantly predicted poorer OS and PFS when
compared with negative expression (Po0.0001). In the multivariate analyses, positive Twist expression was the only independent
prognostic factor for survival in this study (Po0.0001). Positive Twist expression seems to be a useful marker in patients with EOC
likely to have an unfavourable clinical outcome.
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Epithelial ovarian carcinoma (EOC) is a major cause of death
among gynaecological malignancies (Brun et al, 2000). Epithelial
ovarian carcinoma(EOC) has a poor prognosis primarily owing to
its late symptomatology, its frequent association with multiple
intraperitoneal disseminations and high rate of distant metastases.
Patient age, disease stage, tumour type and histological grade
have been shown to have a prognostic value in EOC (Kosary,
1994). Treatment for advanced EOC is difficult because of both
the inability to completely resect the diffuse tumour involve-
ment on the peritoneal surface and the eventual resistance of
the tumour cells to chemotherapy. Most EOC-related deaths
are caused not only by the primary tumour itself but also
by subsequent peritoneal metastases. In the initial step of
peritoneal metastasis, tumour cells are shed from the ovary and
they spread into the peritoneal cavity. The tumour cells then
may attach to the monolayered peritoneal mesothelial cells that
cover the inner surface of the peritoneal cavity. Once EOC
cells adhere to mesothelial cells, the tumour cells may gradually
migrate through the layers of these cells, invade the local region
and spread to distant organs (Coukos and Rubin, 1998; Sood and
Buller, 1998; Lessan et al, 1999). In this multisteps metastasis,
tumour cells proceed from a noninvasive to an invasive, malignant
phenotype (Kajiyama et al, 2002, 2005). During this process,
the morphology of the tumour cells changes from an epithelioid
or cobblestone appearance to a fibroblastic form through a
process referred to as epithelial–mesenchymal transition (EMT)
(Boyer et al, 2000; Savagner, 2001; Vernon and LaBonne, 2004).
Epithelial–mesenchymal transition (EMT) is an important
event in the metastatic step. Decreased expression of E-cadherin
is one of the most common indicators of EMT onset. E-cadherin
which is required for the formation of stable adherens junc-
tions, plays a critical role in the maintenance of the epith-
elial phenotype (Boyer et al, 2000; Thiery, 2002; Vernon and
LaBonne, 2004).
Twist was first identified in Drosophila melanogaster and is a
basic helix–loop–helix transcription factor that is crucial for
mesoderm specification in gastrulating fly embryos and regulates
craniofacial development in mice by inducing cell movement and
tissue reorganization (Thisse et al, 1987; Leptin and Grunewald,
1990). Comijn et al (2001) reported that Twist represses
transcription from E-cadherin promoter via the E boxes that
are also targeted by Snail and SIP1. Consistently, disruption of
E-cadherin-mediated cell adhesion appears to be a crucial event in
the EMT from noninvasive to invasive tumour cells.
Yang et al (2004) reported that suppression of Twist expression
in highly metastatic mammary carcinoma cells specifically inhibits
their metastasis to the lung, and that elevated levels of Twist
mRNA are correlated with the invasive breast cancer phenotype.
These facts prompted us to hypothesize that Twist acts as a
tumour-progression factor for EOC, and that Twist may have
clinical usefulness as a novel molecular target or as a prognostic
indicator in the treatment of EOC. Based on this hypothesis, the
present study examined the immunohistochemical expression
of Twist in EOC tissues to determine whether Twist expression is
correlated with clinicopathological factors or the prognosis of EOC
patients.
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sMATERIALS AND METHODS
Patients and tissue samples
Eighty-two human EOC tissues were obtained from patients who
underwent surgical treatment at Nagoya University Hospital between
1991 and 2004 after informed consent. The age of the patients ranged
from 27 to 79 years, with a median age of 54 years. None of these
patients had undergone neo-adjuvant chemotherapy before
surgery. Surgical treatment consisted of total hysterectomy, bilateral
salpingo-oophorectomy, omentectomy and pelvic and para-aortic
lymphadenectomy. When residual tumour remained, systemic
lymphadenectomy was omitted. The present series consisted of 82
carcinomas that were classified into the following histological types: 32
serous carcinomas, 11 mucinous carcinomas, 27 clear cell carcinomas
and 12 endometrioid carcinomas. The histological cell types and
histological grade (tumour differentiation) were assigned accord-
ing to the criteria of the World Health Organization (WHO)
classification (serous, endometrioid and mucinous type) or
Universal grading system (clear cell type) (Shimizu et al, 1998).
Clinical stage was assigned based on the International Federation
of Gynecology and Obstetrics (FIGO) staging system. In this series,
30 cases were diagnosed with FIGO stage I tumours, 14 with FIGO
stage II, 28 with FIGO stage III and 11 with FIGO stage IV tumours.
All tissue samples were fixed in 10% formalin, embedded in
paraffin and routinely stained with haematoxylin and eosin for
histological examination. The patients received postoperative chemo-
therapy with platinum plus cyclophosphamide and doxorubicin
(before 1997), or platinum plus paclitaxel (after 1997) for high-risk
early stage (stage I with grades 2–3; stage IC; any stage II) or
advanced (stages III and IV) disease. Tumour recurrence/progression
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Figure 1 Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D)
mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell
adenocarcinoma); magnification  100.
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swas defined based on clinical, radiological or histological
diagnosis.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were cut at a
thickness of 4mm. For heat-induced epitope retrieval, deparaffi-
nized sections in 0.01 M citrate buffer (Target Retrieval Solution
pH 6.1, Dako, Kyoto, Japan) were heated three times at 901C for
5min using a microwave oven. Immunohistochemical staining was
performed using the avidin–biotin immunoperoxidase technique
using Histofine SAB-PO kit (Nichirei, Tokyo, Japan) according to
the manufacturer’s protocol. Briefly, endogenous peroxidase
activity was blocked by incubation with 0.3% H2O2 in methanol
for 15min, and nonspecific immunoglobulin binding was blocked
by incubation with 10% normal goat serum for 10min. Sections
were incubated at 41C for 12h with primary antibody (anti-rabbit-
polyclonal, at 1:100 dilution, Santa Cruz Biotech, CA, USA). The
sections were rinsed and incubated for 30min with biotinylated
secondary antibody. After washing, the sections were incubated for
30min with horseradish peroxidase-conjugated streptavidin, and
finally treated with 3-amino-9-ethylcarbazole in 0.01% H2O2 for
10min. The slides were counterstained with Meyer’s haematoxylin.
As a negative control, the primary antibody was replaced with
normal rabbit IgG at an appropriate dilution. The intensity of
immunostaining for Twist was scored semiquantitatively on a
four-tiered scale based on the percent positivity of stained cells as
follows: For the evaluation of Twist expression, the staining
intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3
(strong). The extent of staining was scored as 0 (0%), 1 (1–10%), 2
(10–50%), 3 (51%o) according to the percentage of positive
staining area relative to the total tumour area. The sum of the
intensity and extent scores was used as the final staining score (0–
6) for Twist. Tumours having a final staining score of 3–4 or 5–6
were considered to have moderately or strongly positive expres-
sion, respectively. The scoring procedure was carried out twice
by two independent observers (each blinded to the other’s score)
without any knowledge of the clinical parameters or other
prognostic factors. The concordance rate was over 95% between
the observers.
Western blot analysis
Sample preparation and immunoblot analysis was performed as
described previously (Kajiyama et al, 2003). Briefly, we prepared
various samples of total protein from surgically resected EOC
tissues after patients’ informed consent. Twenty micrograms of
total protein were electrophoresed on a 10% sodium dodecyl
sulphate-polyacryl (SDS)–amide gel and transferred electrophor-
etically to an Immobilon membrane (Millipore, Bedford, MA,
USA). After blocking in blocking solution (5% nonfat dry milk/
0.1% Tween/PBS), the membranes were incubated with a
recommended dilution of primary antibodies overnight. We used
same anti-Twist-antibody (Santa Cruz Biotech, CA, USA) as used
in immunohistochemical staining. We also used anti-b-actin
antibody (Sigma, St Louis, MD, USA) as primary antibodies. The
membrane was incubated with horseradish peroxidase-conjugated
secondary antibody (Chemicon, Temecula, CA, USA). Proteins
were visualized using enhanced chemiluminescence reagent
(Amersham Pharmacia Biotech, Buckinghamshire, England) fol-
lowed by exposure to X-ray film.
Statistical analysis
The association between negative vs positive Twist expression and
clinicopathological parameters was evaluated using the w
2-tests.
The classification of Twist immunoexpression pattern into
negative vs positive expression associated significantly with overall
survival (OS); therefore, this subdivision was used for further
analysis regarding overall and progression-free survival (PFS).
The univariate survival analysis was based on the Kaplan–Meier
method. Comparison between the survival curves was analysed
using the log-rank test. The OS was defined as the time between the
date of surgery and the last date of follow-up or date of death
owing to EOC. The PFS was defined as the time interval between
the date of surgery and the date of progression/recurrence or date
of last follow-up. The prognostic significance of negative Twist
expression concerning other pathological variables was assessed
using the multivariate Cox’s proportional hazard’s analysis. Stat
View software ver.5.0 (SAS, Institution Inc., Cary, NC, USA) was
used for all statistical analyses and a P-value of o0.05 was
considered significant.
RESULTS
Immunohistochemical detection of Twist in EOC tissues
As shown in Figure 1, Twist immunoreactivity was detected at
various levels in EOC. There was little immunoreactivity of Twist
in the tumour stroma. Of the 82 EOC specimens examined in this
study, 33 (40.2%) cases were positive for Twist immunoreactivity,
of which seven cases were strongly positive. Positive expression of
Twist was observed in the following histological types: 14 serous
types (14 out of 32; 43.8%), 13 clear cell types (13 out of 27; 48.1%),
Table 1 Relationship between the expression of Twist and clinico-
pathological parameters in EOC
Twist
No. Negative n Positive nP -value
Total 82 49 33
Age (years) 0.445
455y 43 24 (55.8%) 19 (44.2%)
p55y 39 25 (64.1%) 14 (35.9%)
FIGO stage 0.136
I+II 43 29 (67.4%) 14 (32.6%)
III+IV 39 20 (51.3%) 19 (48.7%)
Histological type 0.605
Serous 32 18 (56.3%) 14 (43.7%)
Nonserous 50 31 (62.0%) 19 (38.0%)
Grade 0.295
G1 33 22 (66.7%) 11 (33.3%)
G2/G3 49 27 (55.1%) 22 (44.9%)
Residual tumour (cm) 0.247
42cm 58 37 (63.8%) 21 (36.2%)
p2cm 24 12 (50.0%) 12 (50.0%)
CA125 (Uml
 1) 0.987
435 10 6 (60.0%) 4 (40.0%)
p35 72 43 (59.7%) 29 (40.3%)
Peritoneal cytology 0.0838
Negative 29 21 (72.4%) 8 (27.6%)
Positive 53 28 (52.8%) 25 (47.2%)
Ascitic fluid volume (ml) 0.163
4100ml 40 27 (67.5%) 13 (32.5%)
p100ml 42 22 (52.4%) 20 (47.6%)
EOC¼ epithelial ovarian carcinoma; FIGO¼ International Federation of Gynecology
and Obstetrics.
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stwo endometrioid types (two out of 12; 16.7%) and four mucinous
types (four out of 11; 36.4%). The Twist immunoreacti-
vity categorised into negative vs positive (moderate and strong
comined) expression was not associated with any of the
clinicopathological parameters tested: age, FIGO stage, histological
type, tumour grade, preoperative value of CA125, the intraopera-
tive volume of ascites, residual tumour after primary cytoreductive
surgery or peritoneal cytology (Table 1). Moreover, to show the
validation of the antibody with respect to the recognition of Twist
protein, we also performed an immunoblot analysis using same
Twist antibody. Figure 2 shows Twist expression in various EOC
tissues including several histological types.
Correlation of Twist expression with survival of EOC
patients
The median OS of the patients was 117 months (range 6–513). At the
end of the follow-up period, 40 (48.8%) patients were alive, 35
(42.7%) patients were dead of the disease and seven (8.5%) patients
were alive with the disease. None of the patients were lost for follow-
up. During the follow-up period, the total number of cases in which
death and progression/recurrence were observed was 35 (42.7%).
The 5-year OS rates of patients who were negative (n¼49) and
positive (n¼33) for expression of Twist were 79.2 and 36.8%,
respectively (Table 2). In univariate analyses, FIGO stage, residual
tumour after primary cytoreductive surgery and positive expres-
sion of Twist were significant predictors of poor OS (Table 2).
In addition, for PFS, five prognostic factors, that is, FIGO stage,
histological type, residual tumour after primary cytoreductive
surgery, positive peritoneal cytology and positive expression of
Twist, were significant (Table 2). Figure 3 shows the OS and PFS
curves with respect to Twist expression. Both OS and PFS in
patients positive for expression of Twist were significantly lower
than those in patients who were negative for Twist expression (OS,
PFS; Po0.0001).
Twist
-Actin
4, clear cell-1
5, clear cell-2
2, serous-1
3, serous-2
1, negative control
6, endometrioid-1
7, endometrioid-2
Figure 2 Immunoblot analysis of Twist expression in various EOC
tissues. Lane 1, negative control (no protein loading); lanes 2 and 3, serous
cystadenocarcinoma; lanes 4 and 5, clear cell adenocarcinoma; lanes 6 and
7; endometrioid adenocarcinoma.
Table 2 Univariate analyses of various clinicopathological parameters in
relation to survival of patients with EOC
Progression-free survival Overall survival
Variable No. 82
5-year
survival (%) P-value
5-year
survival (%) P-value
Age (years)
455 43 56.1 0.0711 52.4 0.3047
p55 39 64.2 64.2
FIGO stage
I–II 43 66.8 40.0001 82.8 40.001
III–IV 39 17.8 40.0
Histological type
Serous 32 21.7 0.0024 51.5 0.2161
Nonserous 50 58.9 69.6
Grade
G1 33 47.5 0.4362 68.4 0.2323
G2/G3 49 41.4 57.0
Residual tumour (cm)
42cm 58 51.3 0.0096 75.1 40.001
p2cm 24 25.0 33.8
CA125 (Uml
 1)
435 10 78.7 0.0979 76.2 0.1926
p35 72 38.4 59.9
Peritoneal cytology
Negative 29 65.0 0.0108 75.1 0.1646
Positive 53 31.2 54.5
Ascitic fluid volume (ml)
4100ml 40 50.4 0.2932 66.8 0.4405
p100ml 42 37.2 54.5
Twist expression
Negative 49 64.1 40.0001 79.2 40.0001
Positive 33 13.0 36.8
EOC¼ epithelial ovarian carcinoma; FIGO¼ International Federation of Gynecology
and Obstetrics.
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Figure 3 Kaplan–Meier survival curves for primary EOCs according to
immunoexpression of Twist. (A) Overall survival (OS), (B) progression-
free survival (PFS). Discontinuous line represents negative Twist expression
(n¼49). Continuous line represents positive Twist immunoexpression
(n¼33). Patients with Twist expression had a significantly worse
carcinoma-specific survival (A; OS, Po0.0001, B; PFS, Po0.0001).
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sWe further divided all cases into two groups according to FIGO
stage (early stage; stage IþII, advanced stage; stage IIIþIV).
There was a significant difference for OS between the two groups
(stage IþII; Po0.0001, advanced stage group; Po0.05, respec-
tively) (Figure 4A and B). Similarly, all cases were stratified
according to histological subtype (serous and nonserous type) and
residual tumour after primary cytoreductive surgery (42
and p2cm). The expression of Twist was a significant prognostic
factor in non-serous type although not in serous type
(OS; Po0.0001 and P¼0.186, respectively) (Figure 4C and D).
Subsequently, we showed that there was also a significant
difference for OS in the two groups with residual tumour size,
less than or greater than smaller than or larger than 2cm (42cm;
Po0.0001, p2cm; Po0.05) (Figure 4E and F).
Multivariate analysis of prognostic variables in EOC
patients
In multivariate OS analyses, FIGO stage, residual tumour and
Twist immunoreactivity were entered into the Cox proportional
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Figure 4 Carcinoma-specific OS rate of EOC patients with Twist expression. Kaplan–Meier survival curves for primary EOCs according to
immunoexpression of Twist stratified with FIGO stage and histological type. (A, B) Kaplan–Meier survival curves stratified with FIGO stage (stages I–II (A;
n¼43) vs III–IV (B;n¼39). (C, D) Kaplan–Meier survival curves stratified with histological type (serous type (C; n¼32) vs nonserous type (D; n¼50)).
(E, F) Kaplan–Meier survival curves stratified with residual tumour after optimal debulking surgery (42cm(E; n¼58) vs p2cm(F; n¼24)). Discontinuous
line represents negative Twist expression. Continuous line represents positive Twist immunoexpression. Stages I–II-, III–IV-, nonserous type-, 42cm
residual tumour and p2cm residual tumour with Twist expression had a significantly worse carcinoma-specific survival (Po0.0001, Po0.05, Po0.0001,
Po0.0001 and Po0.05, respectively).
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shazard analysis. Only the expression of Twist retained its
significance as an independent prognostic factor of poor OS. The
relative risk (RR) for positive Twist expression was 4.489, 95% CI,
2.113–9.537; Po0.0001 (Table 3). Furthermore, multivariate
analysis for PFS including FIGO stage, histological type, residual
tumour, positive peritoneal cytology and Twist immunoreactivity
revealed that FIGO stage and positive Twist expression were
independently significant prognostic factors (FIGO stage: RR,
3.861; 95% CI, 1.615–9.231; Po0.0001; positive immunoexpres-
sion of Twist: RR, 4.436; 95% CI, 2.275–8.652; Po0.0001) (Table 3).
DISCUSSION
There have been various studies demonstrating the involvement of
Twist as a crucial regulator of the metastatic process in certain
malignancies; however, most of those studies were conducted in in
vitro models or in animals (Wang et al, 2004; Yang et al, 2004; Elias
et al, 2005; Mironchik et al, 2005). In the current study of 82 EOC
patients with long-term follow up, high levels of Twist expression
were observed in 40.2% (33 in 82) of the EOC samples, and the
Twist level was not associated with any of the several clinico-
pathological parameters examined. High expression of Twist was
associated with poor survival in both univariate and multivariate
analyses of all factors that influenced survival. There have been a
few other reports showing a correlation between Twist expression
and clinical significance in patients with malignancies. Consistent
with our result, Kyo et al (2006) demonstrated that Twist
expression in endometrial cancers was significantly associated
with the depth of myometrial invasion and shortened survival.
Regarding the mechanism, one possible explanation of our current
finding that Twist expression was linked with poor prognosis is
that this poor prognosis may be partially owing to reduced
expression of E-cadherin and increased metastatic potential of
EOC. However, recent reports showed that there is a close
relationship between Twist expression and the resistance to
paclitaxel.
Paclitaxel is a first-line chemotherapeutic agent that is effective
for the treatment of EOC. Despite the comparatively high
sensitivity of EOC to paclitaxel, the prognosis of advanced or
recurrent cases remains poor as most deaths result from metastasis
that is refractory to conventional chemotherapy. Paclitaxel exerts
its effect through stabilisation of microtubules, induction of cell
cycle arrest in G2–M and activation of proapoptotic signalling
(Horwitz, 1994; Wang et al, 2000). Maestro et al (1999)reported
that the expression of Twist was associated with p53-induced
growth arrest and that this effect was correlated with the ability of
Twist to interfere with the activation of a p53-dependent reporter
and to impair the induction of p53 target genes in response to
DNA damage. In addition, Wang et al (2004) demonstrated that
increased Twist was responsible for the development of acquired
Paclitaxel resistance in nasopharyngeal carcinoma cells and
ectopic expression of Twist conferred resistance to microtubule-
disrupting agents, including paclitaxel. Although, our current cases
were not always treated with paclitaxel alone, unfavourable
prognostic outcome in Twist-expressing EOC patients may be
owing to the role of Twist in p53-induced drug resistance as well as
high metastatic potential to the peritoneum, lymphatic/vascular
canal and other parenchymal organs.
Clinically, our stratification analysis showed that Twist expres-
sion is a significant risk factor even in stage I/II-EOC, as well as in
stage III/IV-EOC. Furthermore, in cases with residual tumour
diameter less than 2cm, the OS of Twist-positive patients was
significantly worse compared to that of Twist-negative patients
(OS; Po0.0001). In the current cases, we observed stage-I patients
with high expression of Twist who displayed distant metastasis
in organs such as liver, lung and brain within 1 or 2 years after
debulking surgery. Additionally, although not all of the patients in
the current study received retroperitoneal lymphadnectomy, 31
cases were shown to be without pelvic and para-aortic lymph node
metastasis after complete surgical staging procedures. Among
these cases, all of the 20 patients whose tumours did not express
Twist were alive, whereas in contrast, 63.6% (seven out of /11) of
patients whose tumours expressed Twist were dead. According
to these results, cases with high expression of Twist should be
followed up carefully even if they are early stage, after optimal
operations and/or without lymph node metastasis. Therefore,
although the prognostic value of Twist needs to be confirmed in a
larger number of patients, our results suggest that the immuno-
histochemical expression of Twist in primary EOC may be a useful
marker for selecting patients with a high risk of suffering an
unfavourable clinical outcome and for stratifying them for better
therapeutic strategies.
Based on morphological criteria, there are four major types of
primary EOC, and the chemosensitivity and biological behaviours
differ among these histologic types. The stratified results of
histological subtyping suggest that Twist is an important prog-
nostic factor in nonserous adenocarcinoma (OS; Po0.0001). In
addition, the survival of Twist-positive patients with serous
adenocarcinoma tended to be shorter than that of Twist-negative
patients, although the difference was not significant (OS;
P¼0.186). However, Twist might also become a prognostic factor
even in serous adenocarcinoma if a larger numbers of cases were
analysed. In general, most patients with serous adenocarcinoma
already display intraperitoneal metastasis at the time of initial
diagnosis because it is the character of this histological type to
readily disseminate to the peritoneum at an early time. In contrast,
histological subtypes such as clear cell carcinoma and mucinous
adenocarcinoma tend to have a lower response rate to anticancer
drugs, including paclitaxel. Although there is a definite difference
among these histological types, it is possible that Twist may be
a crucial factor determining the chemosensitivity or tumour
behaviour. We would like to analyse Twist expression in a larger
number of patients stratified according to individual histological types.
In summary, the clinical evidence obtained in this study gives
support for a possible mechanism for EOC metastasis. If our
findings are validated by prospective studies, Twist expression
Table 3 Multivariate analyses of several clinicopathological parameters in
relation to survival of patients with EOC
Progression-free survival Overall survival
Variable
Relative risk
(95% CI) P-value
Relative
risk (95% CI) P-value
FIGO stage
I–II 1 40.0001 1 0.1648
III–IV 3.861 (1.615–9.231) 1.879 (0.772–4.574)
Histological type
Serous 1 0.8083 (—)
Nonserous 0.930 (0.395–2.065) (—)
Residual tumour (cm)
42cm 1 0.8406 1 0.1257
p2cm 1.081 (0.507–2.305) 1.905 (0.835–4.347)
Peritoneal cytology
Negative 1 0.3915 (—)
Positive 1.391 (0.654–2.960) (—)
Twist expression
Negative 1 40.0001 1 40.0001
Positive 4.436 (2.275–8.652) 4.489 (2.113–9.537)
EOC¼ epithelial ovarian carcinoma; FIGO¼ International Federation of Gynecol-
ogy and Obstetrics.
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scould be useful as a predictive factor for recurrence or metastasis
of EOC. This could improve the current staging of EOC by defining
additional criteria for the administration of systemic therapy in
patients without obvious signs of advanced disease. Perhaps most
important is the identification of Twist expression as a novel target
for clinical therapy.
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